

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Andrew R. Marks et al.	Confirmation No.:	7653
Application No.:	10/809,089	Art Unit:	4173
Filed:	March 25, 2004	Examiner:	B. J. Packard
Title:	NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RyR2) AND USES THEREOF		

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Madam:

Applicants state that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement. No fee is required.

Enclosed please find a copy of the Supplementary European Search Report corresponding to European Patent Application No 05732932.8, mailed on March 27, 2009.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 08-0219, under Order No. 0019240.00596US1 from which the undersigned is authorized to draw.

Respectfully submitted,

Dated: May 13, 2009

/Scott McMurry/
Scott A. McMurry
Registration No.: 61,152
Agent for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP
399 Park Avenue
New York, New York 10022
(212) 295-6282 (telephone)
(212) 230-8888 (facsimile)